Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-masked, Controlled Parallel Group, Multi-center Study of DE-111A (Fixed Dose Combination of Tafluprost and Timolol Eye Drops) on the Treatment of Open Angle Glaucoma or Ocular Hypertension (With Tafluprost Eye Drops as a Comparator)

NCT03822559 is registered in ClinicalTrials.gov with Santen Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT03822559
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03822559 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-masked, Controlled Parallel Group, Multi-center Study of DE-111A (Fixed Dose Combination of Tafluprost and Timolol Eye Drops) on the Treatment of Open Angle Glaucoma or Ocular Hypertension (With Tafluprost Eye Drops as a Comparator)
Lead sponsor
Santen Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
January 20, 2019
Completion date
April 4, 2023
Enrollment
219 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

open-angle glaucoma, ocular hypertension